Products
Online Inquiry
Bezafibrate
Cat. No.:
0225LY-0853
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Bezafibrate is an antilipemic medication that regulates lipid levels by lowering triglycerides and cholesterol, specifically reducing low-density lipoproteins (LDL) while elevating high-density lipoproteins (HDL).
Synonym:
BM15075; 41859-67-0; Bezalip; Cedur; Bezafibrat; Befizal; Bezafibrato; Bezafibratum; Sklerofibrat; Azufibrat; Bezatol; Bezatol SR; BM-15.075; LO 44; BM 15075; BF-759; CCRIS 9085; BM-15075; BM 15.075; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; EINECS 255-567-9; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; Y9449Q51XH; Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-; MFCD00078970; 2-(4-(2-(4-Chlorobenzamido)ethyl)phenoxy)-2-methylpropanoic acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-propanoic acid; Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl-
CAS No.:
41859-67-0
Compound CID:
39042
Formula:
C19H20ClNO4
Formula Weight:
361.82
Specification
Targets&IC50:
PPARγ (murine): 55 μM; PPARδ (murine): 110 μM; PPARα (murine): 90 μM; PPARδ (human): 20 μM; PPARγ (human): 60 μM; PPARα (human): 50 μM
Relative Density:
1.26 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Bezafibrate can be used in cardiovascular pharmacology to study the broad-spectrum activation of PPAR alpha, delta, and gamma.
Library Information
Target:
PPAR
Receptor:
PPARα
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-12
Plate Location:
a2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
260 mg/mL; 718.59 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
15 mg/mL; 41.46 mM
ALogP:
3.868
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
7
